You are here

PBMs

Competition declines among PBM middlemen, analysis finds

Competition declines among PBM middlemen, analysis finds

Benefits Pro

Flag link:

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Medical Marketing and Media

Flag link:

PhRMA hits out at PBMs as lurking middlemen in latest ad

PhRMA hits out at PBMs as lurking middlemen in latest ad

Medical Marketing and Media

DTC advertising

Flag link:

Blue Shield of California looks to cut reliance on CVS, taps Amazon

Blue Shield of California looks to cut reliance on CVS, taps Amazon

Yahoo/Reuters

Mark Cuban Cost Plus Drugs

Flag link:

U.S. Appeals Court invalidates significant components of Oklahoma law governing PBMs

U.S. Appeals Court invalidates significant components of Oklahoma law governing PBMs

Miller & Chevalier

Flag link:

For 2023, Five For-Profit Retailers and PBMs Dominate an Evolving 340B Contract Pharmacy Market

For 2023, Five For-Profit Retailers and PBMs Dominate an Evolving 340B Contract Pharmacy Market

Drug Channels

Express Scripts

Unitedhealth Group

Flag link:

House lawmakers, PBM lobby spar over committee hearing

House lawmakers, PBM lobby spar over committee hearing

BioPharma Dive

Flag link:

On heels of Amgen lawsuit, FTC broadens investigation of PBMs

On heels of Amgen lawsuit, FTC broadens investigation of PBMs

BioPharma Dive

Ascent Health Services

Zinc Health Services

Flag link:

Senate health committee seeks to rein in drug prices with four new bills

Senate health committee seeks to rein in drug prices with four new bills

BioSpace

Flag link:

What you need to know about pharma, PBM execs testifying on insulin prices

What you need to know about pharma, PBM execs testifying on insulin prices

Medical Marketing and Media

Flag link:

Sanders, Cassidy reach deal to increase access to generic prescription drugs, reform PBMs

Sanders, Cassidy reach deal to increase access to generic prescription drugs, reform PBMs

Fierce Healthcare

Flag link:

Four Trends That Will Pop the $250 Billion Gross-to-Net Bubble—and Transform PBMs, Market Access, and Benefit Design

Four Trends That Will Pop the $250 Billion Gross-to-Net Bubble—and Transform PBMs, Market Access, and Benefit Design

Drug Channels

Flag link:

A sign of what's coming? Presidential hopeful DeSantis targets PBMs and pharma transparency

A sign of what's coming? Presidential hopeful DeSantis targets PBMs and pharma transparency

Endpoints

Flag link:

House oversight chair calls for investigation into PBMs' tactics to increase drug costs

House oversight chair calls for investigation into PBMs' tactics to increase drug costs

Endpoints

Flag link:

PBM trade group ad campaign hits back at drugmakers over prescription drug prices

PBM trade group ad campaign hits back at drugmakers over prescription drug prices

Medical Marketing and Media

Flag link:

Senate begins quest to demystify PBMs' practices as it mulls legislation

Senate begins quest to demystify PBMs' practices as it mulls legislation

Endpoints

Flag link:

Years after the first US biosim launches, doctors still have their concerns: survey

Years after the first US biosim launches, doctors still have their concerns: survey

Fierce Pharma

Flag link:

Novartis CEO, as incoming PhRMA chair, outlines 3 priorities for pharma after IRA setback

Novartis CEO, as incoming PhRMA chair, outlines 3 priorities for pharma after IRA setback

Fierce Pharma

Inflation Reduction Act

small molecule drugs

Flag link:

PBMs likely to be a focus in 118th Congress

PBMs likely to be a focus in 118th Congress

Roll Call

Flag link:

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars

Drug Channels

Express Scripts

Flag link:

Pages